Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.38 |
| ▸ | CA1 | P00915 | 7/20 | 0.37 |
| ▸ | CA2 | P00918 | 7/20 | 0.37 |
| ▸ | CA12 | O43570 | 5/20 | 0.37 |
| ▸ | CA9 | Q16790 | 5/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | FPR3 | P25089 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13769765 | 0.89 | ACACB (0.39) | MTNR1AMTNR1BMEN1NPC1HTT | |
| SCHEMBL20438815 | 0.80 | TRPV1 (0.40) | MTNR1AMTNR1BEPHX1NQO2 | |
| SCHEMBL3666516 | 0.79 | EPHX2 (0.41) | MEN1NPC1HTTRAB9AKMT2A | |
| SCHEMBL20438820 | 0.79 | FPR3 (0.39) | MTNR1AMTNR1BCA1CA2CA12 | |
| SCHEMBL13751294 | 0.74 | AAK1 (0.39) | CA1CA2CA9IDO1MEN1 | |
| SCHEMBL20505740 | 0.73 | EPHX2 (0.50) | MTNR1AMTNR1BBCHEIDO1 | |
| SCHEMBL29572544 | 0.73 | EPHX2 (0.50) | MTNR1AMTNR1BBCHEIDO1 | |
| SCHEMBL29960099 | 0.71 | MTNR1A (0.45) | MTNR1AMTNR1BEPHX1IDO1 | |
| SCHEMBL20438819 | 0.71 | MTNR1A (0.40) | MTNR1AMTNR1BEPHX1BCHEFPR3 | |
| SCHEMBL6797874 | 0.68 | EPHX1 (0.47) | EPHX1DDB1CRBNMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231668-A1 | CONDENSED PENTACYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF FLAVIVIRIDAE INFECTIONS | GlaxoSmithKline LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090197856-A1 | ANTIVIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197856-A1 | ANTIVIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2009-08-06 | — | — | US | disclosed |
| WO-2009086139-A1 | CONDENSED PENTACYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF FLAVIVIRIDAE INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197856-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, EIF2AK2, MAVS | MTNR1A 3712/4885MTNR1B 4047/4885CA1 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.